Publications
135
Citations
2,496
Est. group size
~1
Recurring co-author estimate
Active years
19
Publishing since 2008
Typically publishes in teams of ~5 · 14% small-team papers (≤3 authors) · across 27 venues
- 26-A-14402-ACC CLINICAL IMPLICATIONS ASSOCIATED WITH TEMPORARY TREATMENT INTERRUPTION AND REINITIATION OF AFICAMTEN THERAPY IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Journal of the American College of Cardiology · 2026
- Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients
The American Journal of Cardiology · 2026
- Genotype Predicts Heart Failure Independent of LVEF, Peak VO2, and NT-proBNP Levels in Hypertrophic Cardiomyopathy
JACC Heart Failure · 2026
- Cardiomyopathies
Medicine · 2026
- A More Accurate Diagnosis of Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology · 2025
- Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma
JACC CardioOncology · 2025
- Transcatheter Amplatz canine duct occluder placement for patent ductus arteriosus occlusion: a retrospective analysis of outcomes and complications in 200 dogs
Journal of Veterinary Cardiology · 2025
- A Case of Left-Dominant Arrhythmogenic Cardiomyopathy Presenting with Cardiac Arrest
British Journal of Hospital Medicine · 2025
- British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of adult patients with obstructive hypertrophic cardiomyopathy receiving myosin-inhibitor therapy
Echo Research and Practice · 2025
- 1-036 RIDGE <sup>TM</sup> -1: a phase 1b interventional study to evaluate safety and efficacy of TN-401, an adeno-associated virus serotype 9 (AAV9) investigational gene therapy, in adults with <i>PKP2</i> -associated arrhythmogenic right ventricular cardiomyopathy (ARVC)
2025
- 1-026 Evaluating the pathogenic potential of a variant of unknown significance in filamin C
2025
- 1-016 Evaluating the concordance of ATTR amyloidosis recording between primary and secondary care electronic healthcare data using general practice survey feedback
2025
- Abstract 4370461: Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study
Circulation · 2025
- Abstract 4336093: Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy
Circulation · 2025
- Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial
Circulation · 2025
- Journal of the American College of Cardiology×16
- European Heart Journal×10
- Circulation×6
- Journal of Cardiac Failure×5
- JACC Heart Failure×4
- Michael A. Fifer
Medicine · University of Michigan
- Sara Saberi
Medicine · University of Michigan
- Anjali Owens
Medicine · University of Michigan
- Martin S. Maron
Medicine · University of Michigan
- Iacopo Olivotto
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile